Babich Oren, Lugassy Erel, Babich Michael, Abayov Pinny, Haimov Eliezer, Juodzbalys Gintaras
Department of Maxillofacial Surgery, Faculty of Odontology, Medical Academy, Lithuanian University of Health Sciences, KaunasLithuania.
J Oral Maxillofac Res. 2024 Jun 30;15(2):e1. doi: 10.5037/jomr.2024.15201. eCollection 2024 Apr-Jun.
This systematic review aims to critically assess the impact of platelet-rich fibrin on maxillary sinus floor augmentation and outline the specific aspects of new bone formation, bone height, implant stability quotient, and Schneiderian membrane thickness.
A systematic review and meta-analysis were conducted, analysing studies from MEDLINE (PubMed), the Cochrane Library, and ScienceDirect databases, published from January 29, 2018 until January 29, 2024 that compared maxillary sinus floor augmentation (MSFA) using bone graft material with and without platelet-rich fibrin (PRF). This review focused on patients 18 years and older who undergone MSFA before the dental implant placement. It systematically examined five studies, encompassing randomized controlled trials, and reported on 112 MSFA procedures conducted in 84 patients.
The meta-analysis reveals a marginal significance in new bone formation with PRF, suggesting a trend towards beneficial outcomes that were not statistically significant. No significant impact on bone height was observed. However, a notable improvement in implant stability quotient (ISQ) was recorded, indicating enhanced implant stability with PRF. The Schneiderian membrane thickness did not show significant changes post-treatment with PRF.
While platelet-rich fibrin shows promise in enhancing implant stability, its effects on new bone formation and Schneiderian membrane thickness are inconclusive, highlighting the need for further research. Platelet-rich fibrin did not significantly affect bone height. The findings support platelet-rich fibrin's potential as a beneficial adjunct in maxillary sinus floor augmentation, particularly for implant stability.
本系统评价旨在严格评估富血小板纤维蛋白对上颌窦底提升的影响,并概述新骨形成、骨高度、种植体稳定性商数和施奈德膜厚度的具体方面。
进行了一项系统评价和荟萃分析,分析了2018年1月29日至2024年1月29日期间发表在MEDLINE(PubMed)、Cochrane图书馆和ScienceDirect数据库中的研究,这些研究比较了使用和不使用富血小板纤维蛋白(PRF)的骨移植材料进行上颌窦底提升(MSFA)的情况。本评价聚焦于18岁及以上在种植牙植入前接受过MSFA的患者。系统审查了五项研究,包括随机对照试验,并报告了84例患者进行的112次MSFA手术。
荟萃分析显示PRF在新骨形成方面有微弱的显著性,表明有有益结果的趋势,但无统计学意义。未观察到对骨高度有显著影响。然而,记录到种植体稳定性商数(ISQ)有显著改善,表明PRF可增强种植体稳定性。PRF治疗后施奈德膜厚度未显示出显著变化。
虽然富血小板纤维蛋白在增强种植体稳定性方面显示出前景,但其对新骨形成和施奈德膜厚度的影响尚无定论,这突出了进一步研究的必要性。富血小板纤维蛋白对骨高度没有显著影响。这些发现支持富血小板纤维蛋白作为上颌窦底提升中有益辅助材料的潜力,特别是在种植体稳定性方面。